Shanghai, China, and Santiago de Compostela, Spain. June 16, 2025. Escugen and SunRock Biopharma and have joined forces in a strategic partnership to co-develop SRB123 a First-in-Class antibody-drug conjugate (ADC) targeting C-C motif chemokine receptor 9 (CCR9), a tumor-associated antigen overexpressed in multiple solid tumors, including pancreatic, ovarian and lung cancer.

June 12, 2025 — Shanghai Escugen Biotechnology Co., Ltd. and Sovran Bio, Inc. jointly announced today the signing of a strategic collaboration agreement. This collaboration aims to leverage Sovran's novel approach to broad-spectrum disease targeting and unique biologic architectures together with Escugen's proprietary EZWi-Fit^® platform technology and deep development expertise to rapidly advance multiple novel antibody and antiody-drug conjugate (ADC) therapeutic product candidates to the clinical. Under the agreement, the parties will jointly contribute to partnered program research and development with shared upside.